Clinical trialObsCompleted
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Prevalence Estimation of BRCA1, BRCA2 and Other Germline Mutations Associated With Hereditary Pancreatic Cancer Using a Comprehensive Gene Panel in an Unselected Cohort of Patients With Pancreatic Adenocarcinoma in Mexico
- Outcome
- Finished, no results posted
- Phase
- Obs
- Status
- Completed
- Study type
- Observational
- Start
- 9 September 2020
- Expected end
- 30 June 2022
- Enrollment
- 107 participants
- Sites
- 1
- Primary outcomes
- BRCA 1/2 germline mutation prevalence
- Sponsor
- Other
- Results posted
- No
- Last update
- 18 October 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- BackgroundMaintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. DOI 10.1056/nejmoa1903387↗
- BackgroundEpidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. DOI 10.14740/wjon1166↗
- BackgroundPrevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. DOI 10.1002/cncr.26191↗